Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

Investigator: Jun Zhang, MD

Study Coordinator: Juan Morales Viera

Status: Enrolling

ClinicalTrials.gov Number: NCT03833154

Phone: 786.803.2333

Protocol Number: Pro00021863


This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.
More to Explore